Skip to main content
Erschienen in: Cancer Causes & Control 5/2008

01.06.2008 | Original Paper

Accuracy of self-reported family history of cancer in a large case–control study of ovarian cancer

verfasst von: Marie Soegaard, Allan Jensen, Kirsten Frederiksen, Estrid Høgdall, Claus Høgdall, Jan Blaakær, Susanne K. Kjaer

Erschienen in: Cancer Causes & Control | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

Objective

To evaluate the reliability of self-reported family history of cancer in first-degree female relatives and to examine possible determinants of accurate reporting.

Methods

Women with ovarian cancer and controls were recruited between 1995 and 1999 and interviewed. The study comprised 579 cases and 1,564 controls with 6,265 first-degree female relatives. Self-reported familial cancer diagnoses were validated from registry data. Sensitivity, specificity, and kappa were calculated, and possible determinants were examined by logistic regression.

Results

The sensitivity of self-reporting ranged from 0.78 to 0.90 for all cancers but was lower for self-reporting of most site-specific cancers, ranging from 0.29 to 0.94. The specificity of self-reporting ranged from 0.91 to 0.99 for cancer in general and from 0.99 to 1.00 for site-specific cancers. Type of relative, age at interview, and length of education influenced the sensitivity and specificity significantly. The odds ratio for ovarian cancer was higher when based on registry data than on self-reported data and was significant (OR = 2.58 vs. 1.56).

Conclusions

Cancer diagnoses in first-degree relatives are not always accurately reported by patients with ovarian cancer or by controls. The results indicate that studies of associations with family cancer history should validate self-reported family cancer diagnoses as carefully as possible.
Literatur
1.
Zurück zum Zitat Kerber RA, Slattery ML (1997) Comparison of self-reported and database-linked family history of cancer data in a case-control study. Am J Epidemiol 146:244–248PubMed Kerber RA, Slattery ML (1997) Comparison of self-reported and database-linked family history of cancer data in a case-control study. Am J Epidemiol 146:244–248PubMed
2.
Zurück zum Zitat Mitchell RJ, Brewster D, Campbell H et al (2004) Accuracy of reporting of family history of colorectal cancer. Gut 53:291–295PubMedCrossRef Mitchell RJ, Brewster D, Campbell H et al (2004) Accuracy of reporting of family history of colorectal cancer. Gut 53:291–295PubMedCrossRef
3.
Zurück zum Zitat Parent ME, Ghadirian P, Lacroix A, Perret C (1995) Accuracy of reports of familial breast cancer in a case-control series. Epidemiology 6:184–186PubMedCrossRef Parent ME, Ghadirian P, Lacroix A, Perret C (1995) Accuracy of reports of familial breast cancer in a case-control series. Epidemiology 6:184–186PubMedCrossRef
4.
Zurück zum Zitat Sijmons RH, Boonstra AE, Reefhuis J et al (2000) Accuracy of family history of cancer: clinical genetic implications. Eur J Hum Genet 8:181–186PubMedCrossRef Sijmons RH, Boonstra AE, Reefhuis J et al (2000) Accuracy of family history of cancer: clinical genetic implications. Eur J Hum Genet 8:181–186PubMedCrossRef
5.
Zurück zum Zitat Ziogas A, Anton-Culver H (2003) Validation of family history data in cancer family registries. Am J Prev Med 24:190–198PubMedCrossRef Ziogas A, Anton-Culver H (2003) Validation of family history data in cancer family registries. Am J Prev Med 24:190–198PubMedCrossRef
6.
Zurück zum Zitat Love RR, Evans AM, Josten DM (1985) The accuracy of patient reports of a family history of cancer. J Chronic Dis 38:289–293PubMedCrossRef Love RR, Evans AM, Josten DM (1985) The accuracy of patient reports of a family history of cancer. J Chronic Dis 38:289–293PubMedCrossRef
7.
Zurück zum Zitat Douglas FS, O’Dair LC, Robinson M, Evans DG, Lynch SA (1999) The accuracy of diagnoses as reported in families with cancer: a retrospective study. J Med Genet 36:309–312PubMed Douglas FS, O’Dair LC, Robinson M, Evans DG, Lynch SA (1999) The accuracy of diagnoses as reported in families with cancer: a retrospective study. J Med Genet 36:309–312PubMed
8.
Zurück zum Zitat Glanz K, Grove J, Le ML, Gotay C (1999) Underreporting of family history of colon cancer: correlates and implications. Cancer Epidemiol Biomarkers Prev 8:635–639PubMed Glanz K, Grove J, Le ML, Gotay C (1999) Underreporting of family history of colon cancer: correlates and implications. Cancer Epidemiol Biomarkers Prev 8:635–639PubMed
9.
Zurück zum Zitat Ivanovich J, Babb S, Goodfellow P et al (2002) Evaluation of the family history collection process and the accuracy of cancer reporting among a series of women with endometrial cancer. Clin Cancer Res 8:1849–1856PubMed Ivanovich J, Babb S, Goodfellow P et al (2002) Evaluation of the family history collection process and the accuracy of cancer reporting among a series of women with endometrial cancer. Clin Cancer Res 8:1849–1856PubMed
10.
Zurück zum Zitat King TM, Tong L, Pack RJ, Spencer C, Amos CI (2002) Accuracy of family history of cancer as reported by men with prostate cancer. Urology 59:546–550PubMedCrossRef King TM, Tong L, Pack RJ, Spencer C, Amos CI (2002) Accuracy of family history of cancer as reported by men with prostate cancer. Urology 59:546–550PubMedCrossRef
11.
Zurück zum Zitat Aitken JF, Youl P, Green A, MacLennan R, Martin NG (1996) Accuracy of case-reported family history of melanoma in Queensland, Australia. Melanoma Res 6:313–317PubMedCrossRef Aitken JF, Youl P, Green A, MacLennan R, Martin NG (1996) Accuracy of case-reported family history of melanoma in Queensland, Australia. Melanoma Res 6:313–317PubMedCrossRef
12.
Zurück zum Zitat Chang ET, Smedby KE, Hjalgrim H, Glimelius B, Adami HO (2006) Reliability of self-reported family history of cancer in a large case–control study of lymphoma. J Natl Cancer Inst 98:61–68PubMedCrossRef Chang ET, Smedby KE, Hjalgrim H, Glimelius B, Adami HO (2006) Reliability of self-reported family history of cancer in a large case–control study of lymphoma. J Natl Cancer Inst 98:61–68PubMedCrossRef
13.
Zurück zum Zitat Garbers V, Toniolo PG, Taioli E (2001) Changes in self-reported family history of breast cancer with change in case–control status. Eur J Epidemiol 17:517–520PubMedCrossRef Garbers V, Toniolo PG, Taioli E (2001) Changes in self-reported family history of breast cancer with change in case–control status. Eur J Epidemiol 17:517–520PubMedCrossRef
14.
Zurück zum Zitat Koch M, Hill GB (1987) Problems in establishing accurate family history in patients with ovarian cancer of epithelial origin. Cancer Detect Prev 10:279–283PubMed Koch M, Hill GB (1987) Problems in establishing accurate family history in patients with ovarian cancer of epithelial origin. Cancer Detect Prev 10:279–283PubMed
15.
Zurück zum Zitat Aitken J, Bain C, Ward M, Siskind V, MacLennan R (1995) How accurate is self-reported family history of colorectal cancer? Am J Epidemiol 141:863–871PubMed Aitken J, Bain C, Ward M, Siskind V, MacLennan R (1995) How accurate is self-reported family history of colorectal cancer? Am J Epidemiol 141:863–871PubMed
16.
Zurück zum Zitat Rauscher GH, Sandler DP (2005) Validating cancer histories in deceased relatives. Epidemiology 16:262–265PubMedCrossRef Rauscher GH, Sandler DP (2005) Validating cancer histories in deceased relatives. Epidemiology 16:262–265PubMedCrossRef
17.
Zurück zum Zitat Amos CI, Struewing JP (1993) Genetic epidemiology of epithelial ovarian cancer. Cancer 71(2 Suppl):566–572PubMed Amos CI, Struewing JP (1993) Genetic epidemiology of epithelial ovarian cancer. Cancer 71(2 Suppl):566–572PubMed
18.
Zurück zum Zitat Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA (1998) A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 105:493–499PubMed Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA (1998) A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 105:493–499PubMed
19.
Zurück zum Zitat Gayther SA, Russell P, Harrington P, Antoniou AC, Easton DF, Ponder BA (1999) The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet 65:1021–1029PubMedCrossRef Gayther SA, Russell P, Harrington P, Antoniou AC, Easton DF, Ponder BA (1999) The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet 65:1021–1029PubMedCrossRef
20.
Zurück zum Zitat Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676–689PubMedCrossRef Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676–689PubMedCrossRef
21.
Zurück zum Zitat Glud E, Kjaer SK, Thomsen BL et al (2004) Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 164:2253–2259PubMedCrossRef Glud E, Kjaer SK, Thomsen BL et al (2004) Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 164:2253–2259PubMedCrossRef
22.
Zurück zum Zitat Osterlind A, Jensen OM (1985) [Evaluation of cancer registration in Denmark in 1977. Preliminary evaluation of cancer registration by the Cancer Register and the National Patient Register]. Ugeskr Laeger 147:2483–2488PubMed Osterlind A, Jensen OM (1985) [Evaluation of cancer registration in Denmark in 1977. Preliminary evaluation of cancer registration by the Cancer Register and the National Patient Register]. Ugeskr Laeger 147:2483–2488PubMed
23.
Zurück zum Zitat Storm HH (1988) Completeness of cancer registration in Denmark 1943–1966 and efficacy of record linkage procedures. Int J Epidemiol 17:44–49PubMedCrossRef Storm HH (1988) Completeness of cancer registration in Denmark 1943–1966 and efficacy of record linkage procedures. Int J Epidemiol 17:44–49PubMedCrossRef
24.
Zurück zum Zitat World Health Organization (1955) Report of the International Conference for the Seventh Revision of the International Lists of Diseases and Causes of Death, Geneva World Health Organization (1955) Report of the International Conference for the Seventh Revision of the International Lists of Diseases and Causes of Death, Geneva
25.
Zurück zum Zitat Rothman KJ (2002) Epidemiology. An introduction. Oxford University Press: Oxford, pp 98–101 Rothman KJ (2002) Epidemiology. An introduction. Oxford University Press: Oxford, pp 98–101
26.
Zurück zum Zitat Altman DG (1991) Practical statistics for medical research. Chapman & Hall, pp. 404–408 Altman DG (1991) Practical statistics for medical research. Chapman & Hall, pp. 404–408
27.
Zurück zum Zitat Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159–174PubMedCrossRef Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159–174PubMedCrossRef
28.
Zurück zum Zitat Soegaard M, Jensen A, Hogdall E, et al (2007) Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA Study. Cancer Epidemiol Biomarkers Prev 16:1160–1166PubMedCrossRef Soegaard M, Jensen A, Hogdall E, et al (2007) Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA Study. Cancer Epidemiol Biomarkers Prev 16:1160–1166PubMedCrossRef
29.
Zurück zum Zitat Murff HJ, Spigel DR, Syngal S (2004) Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 292:1480–1489PubMedCrossRef Murff HJ, Spigel DR, Syngal S (2004) Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 292:1480–1489PubMedCrossRef
30.
Zurück zum Zitat Parent ME, Ghadirian P, Lacroix A, Perret C (1997) The reliability of recollections of family history: implications for the medical provider. J Cancer Educ 12:114–120PubMed Parent ME, Ghadirian P, Lacroix A, Perret C (1997) The reliability of recollections of family history: implications for the medical provider. J Cancer Educ 12:114–120PubMed
31.
Zurück zum Zitat Risch HA, McLaughlin JR, Cole DE, et al (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700–710PubMedCrossRef Risch HA, McLaughlin JR, Cole DE, et al (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700–710PubMedCrossRef
32.
Zurück zum Zitat Boyd J, Rubin SC (1997) Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol 64:196–206PubMedCrossRef Boyd J, Rubin SC (1997) Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol 64:196–206PubMedCrossRef
Metadaten
Titel
Accuracy of self-reported family history of cancer in a large case–control study of ovarian cancer
verfasst von
Marie Soegaard
Allan Jensen
Kirsten Frederiksen
Estrid Høgdall
Claus Høgdall
Jan Blaakær
Susanne K. Kjaer
Publikationsdatum
01.06.2008
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 5/2008
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-007-9108-3

Weitere Artikel der Ausgabe 5/2008

Cancer Causes & Control 5/2008 Zur Ausgabe

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.